Aeglea BioTherapeutics
classical a rare metabolic disorder with serious and potentially deadly complications classical | Aeglea BioTherapeutics
Company
Deck Type
Sector
Industry
Deck date
March 2023
Slide
8 of 39
Similar slides by Aeglea BioTherapeutics
See diffirences between slides (animation)
Investor Presentation
May 2023
classical a rare metabolic disorder with serious and potentially deadly complications classical | Aeglea BioTherapeutics
Investor Presentation
April 2023
classical a rare metabolic disorder with serious and potentially deadly complications classical | Aeglea BioTherapeutics
Related slides by other companies
Alkermes
Investor Day
March 2021
potential indications in neurodegenerative and disorders with cognitive deficits indications that share common of synaptic dysfunction in hippocampus with deficits in cognition includes certain autism spectrum disorders with reduced synaptic density initial clinical focus on rare and orphan diseases with potential expedited development pathways plan to select lead indications based on preclinical and human data potential indications focused on rare and orphan diseases neurodegenerative disease dementia in down syndrome syndrome syndrome syndrome tuberous sclerosis complex pay by | Alkermes
Other recent decks by Aeglea BioTherapeutics
See all presentations (14 decks)
Investor Presentation
October 2023
Investor Presentation
October 2023
Investor Presentation
September 2023
Investor Presentation
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io